COMMUNIQUÉS West-GlobeNewswire

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
14/07/2026
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
Visory Health Wins a Digital Health Award for Second Consecutive Year
14/07/2026
The win recognizes the app for its real-time pricing and digital Rx savings card, which help users cut prescription costs by up to 80% - no insurance or coupons required ESTERO, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform
14/07/2026
Rural King customers can now shop medications, prescription food and other pet health products through a co-branded digital experience DELRAY BEACH, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing [...]
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14/07/2026
SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new [...]
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
14/07/2026
Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic colorectal cancer expected to commence in Q3 2026 PRAGUE and BASEL, Switzerland and BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- SOTIO Biotech [...]
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14/07/2026
BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a paper titled " [...]
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No [...]
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14/07/2026
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, [...]
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
14/07/2026
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics OXFORD, United Kingdom, July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and [...]
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
14/07/2026
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once [...]
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards
14/07/2026
From 647 applications worldwide, Hummingbird Bioscience was selected by an independent judging panel as a winner at the AI Discovery Awards hosted by Nebius The awards program spotlights companies leveraging AI to [...]
Transactions in connection with share buy-back program
14/07/2026
Company announcement no. 25 - 26 14 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
14/07/2026
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, [...]
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
14/07/2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related [...]

Pages